Ivermectin (MK-933) 是一种广谱的抗寄生虫药物。Ivermectin (MK-933) 是一种特异性的Impα/β1 介导的核导入抑制剂,对 HIV-1 和登革热病毒都具有很强的抗病毒活性。Ivermectin (MK-933) 也是P2X4和 α7nAChRs的正异构效应物。Ivermectin 还可抑制牛疱疹病毒 1 (BoHV-1) 复制并抑制BoHV-1DNA 聚合酶的核输入。Ivermectin 是应用于抗SARS-CoV-2/COVID-19的候选药物。
生物活性 | Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor ofImpα/β1-mediated nuclear importand has potent antiviral activity towards bothHIV-1and dengue virus. It is a positive allosteric effector ofP2X4and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibitsbovine herpesvirus1 (BoHV-1)replication and inhibitsBoHV-1DNA polymerase nuclear import[1][2][3][4]. Ivermectin is a candidate therapeutic againstSARS-CoV-2/COVID-19[5]. |
IC50& Target[1] | HIV-1 | HSV-1 | BoHV-1 | SARS-CoV-2 |
|
体外研究 (In Vitro) | In the submicromolar range (EC50=250 nM) the action of Ivermectin (MK-933) is rapid and reversible, resulting in increased amplitude and slowed deactivation of P2X4channel currents evoked by ATP[1]. Ivermectin (MK-933) markedly increases the potency of ATP and that of the normally low-potency agonist a,b-methylene-ATP in a use- and voltage-independent manner without changing the ion selectivity of P2X4channels[1]. Ivermectin (MK-933) activates glutamate-gated chloride channels in the nerves and muscles of the parasite, leading to membrane hyperpolarization and muscle paralysis[2]. Ivermectin (MK-933) strongly inhibits the binding of Impα/β1 to NS5 (IC50=17 μM), but not of Impβ1 alone to NS5[3]. Ivermectin (MK-933) has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively[3].
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | - Antibiotics
- Macrolide Antibiotics
|
来源 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 250 mg/mL(285.68 mM;Need ultrasonic) H2O :< 0.1 mg/mL (ultrasonic)(insoluble) 配制储备液 1 mM | 1.1427 mL | 5.7137 mL | 11.4274 mL | 5 mM | 0.2285 mL | 1.1427 mL | 2.2855 mL | 10 mM | 0.1143 mL | 0.5714 mL | 1.1427 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (2.86 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (2.38 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|